Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125


The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib.

Marzi L, Szabova L, Gordon M, Weaver Ohler Z, Sharan SK, Beshiri ML, Etemadi M, Murai J, Kelly K, Pommier Y.

Clin Cancer Res. 2019 Oct 15;25(20):6206-6216. doi: 10.1158/1078-0432.CCR-19-0419. Epub 2019 Aug 13.


Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies.

Murai J, Thomas A, Miettinen M, Pommier Y.

Pharmacol Ther. 2019 Sep;201:94-102. doi: 10.1016/j.pharmthera.2019.05.009. Epub 2019 May 23. Review.


Phosphatase 1 Nuclear Targeting Subunit, a Novel DNA Repair Partner of PARP1.

Murai J, Pommier Y.

Cancer Res. 2019 May 15;79(10):2460-2461. doi: 10.1158/0008-5472.CAN-19-0798.


Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.

Haynes B, Murai J, Lee JM.

Cancer Treat Rev. 2018 Dec;71:1-7. doi: 10.1016/j.ctrv.2018.09.003. Epub 2018 Sep 11. Review.


Low muscle quality in Japanese type 2 diabetic patients with visceral fat accumulation.

Murai J, Nishizawa H, Otsuka A, Fukuda S, Tanaka Y, Nagao H, Sakai Y, Suzuki M, Yokota S, Tada H, Doi M, Fujishima Y, Kita S, Funahashi T, Maeda N, Nakamura T, Shimomura I.

Cardiovasc Diabetol. 2018 Aug 4;17(1):112. doi: 10.1186/s12933-018-0755-3.


Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors.

Marzi L, Agama K, Murai J, Difilippantonio S, James A, Peer CJ, Figg WD, Beck D, Elsayed MSA, Cushman M, Pommier Y.

Mol Cancer Ther. 2018 Aug;17(8):1694-1704. doi: 10.1158/1535-7163.MCT-18-0028. Epub 2018 May 10.


The evolving landscape of predictive biomarkers of response to PARP inhibitors.

Thomas A, Murai J, Pommier Y.

J Clin Invest. 2018 May 1;128(5):1727-1730. doi: 10.1172/JCI120388. Epub 2018 Apr 16.


Mitochondrial tyrosyl-DNA phosphodiesterase 2 and its TDP2S short isoform.

Huang SN, Dalla Rosa I, Michaels SA, Tulumello DV, Agama K, Khiati S, Jean SR, Baechler SA, Factor VM, Varma S, Murai J, Miller Jenkins LM, Kelley SO, Pommier Y.

EMBO Rep. 2018 Mar;19(3). pii: e42139. doi: 10.15252/embr.201642139. Epub 2018 Feb 9.


SLFN11 Blocks Stressed Replication Forks Independently of ATR.

Murai J, Tang SW, Leo E, Baechler SA, Redon CE, Zhang H, Al Abo M, Rajapakse VN, Nakamura E, Jenkins LMM, Aladjem MI, Pommier Y.

Mol Cell. 2018 Feb 1;69(3):371-384.e6. doi: 10.1016/j.molcel.2018.01.012.


Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11) Expression with Class I Histone Deacetylase Inhibitors.

Tang SW, Thomas A, Murai J, Trepel JB, Bates SE, Rajapakse VN, Pommier Y.

Clin Cancer Res. 2018 Apr 15;24(8):1944-1953. doi: 10.1158/1078-0432.CCR-17-0443. Epub 2018 Feb 1.


ALC1/CHD1L, a chromatin-remodeling enzyme, is required for efficient base excision repair.

Tsuda M, Cho K, Ooka M, Shimizu N, Watanabe R, Yasui A, Nakazawa Y, Ogi T, Harada H, Agama K, Nakamura J, Asada R, Fujiike H, Sakuma T, Yamamoto T, Murai J, Hiraoka M, Koike K, Pommier Y, Takeda S, Hirota K.

PLoS One. 2017 Nov 17;12(11):e0188320. doi: 10.1371/journal.pone.0188320. eCollection 2017.


Quantitative Structure-Cytotoxicity Relationship of Newly Synthesized Piperic Acid Esters.

Sakagami H, Uesawa Y, Masuda Y, Tomomura M, Yokose S, Miyashiro T, Murai J, Takao K, Kanamoto T, Terakubo S, Kagaya H, Nakashima H, Sugita Y.

Anticancer Res. 2017 Nov;37(11):6161-6168.


Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer.

Ballestrero A, Bedognetti D, Ferraioli D, Franceschelli P, Labidi-Galy SI, Leo E, Murai J, Pommier Y, Tsantoulis P, Vellone VG, Zoppoli G.

J Transl Med. 2017 Oct 2;15(1):199. doi: 10.1186/s12967-017-1296-3.


Association of Epicardial, Visceral, and Subcutaneous Fat With Cardiometabolic Diseases.

Sato F, Maeda N, Yamada T, Namazui H, Fukuda S, Natsukawa T, Nagao H, Murai J, Masuda S, Tanaka Y, Obata Y, Fujishima Y, Nishizawa H, Funahashi T, Shimomura I.

Circ J. 2018 Jan 25;82(2):502-508. doi: 10.1253/circj.CJ-17-0820. Epub 2017 Sep 27.


Targeting DNA repair and replication stress in the treatment of ovarian cancer.

Murai J.

Int J Clin Oncol. 2017 Aug;22(4):619-628. doi: 10.1007/s10147-017-1145-7. Epub 2017 Jun 22. Review.


A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress.

Bruno PM, Liu Y, Park GY, Murai J, Koch CE, Eisen TJ, Pritchard JR, Pommier Y, Lippard SJ, Hemann MT.

Nat Med. 2017 Apr;23(4):461-471. doi: 10.1038/nm.4291. Epub 2017 Feb 27.


Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.

Murai J, Feng Y, Yu GK, Ru Y, Tang SW, Shen Y, Pommier Y.

Oncotarget. 2016 Nov 22;7(47):76534-76550. doi: 10.18632/oncotarget.12266.


In vivo evidence for translesion synthesis by the replicative DNA polymerase δ.

Hirota K, Tsuda M, Mohiuddin, Tsurimoto T, Cohen IS, Livneh Z, Kobayashi K, Narita T, Nishihara K, Murai J, Iwai S, Guilbaud G, Sale JE, Takeda S.

Nucleic Acids Res. 2016 Sep 6;44(15):7242-50. doi: 10.1093/nar/gkw439. Epub 2016 May 16.


SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.

Tang SW, Bilke S, Cao L, Murai J, Sousa FG, Yamade M, Rajapakse V, Varma S, Helman LJ, Khan J, Meltzer PS, Pommier Y.

Clin Cancer Res. 2015 Sep 15;21(18):4184-93. doi: 10.1158/1078-0432.CCR-14-2112. Epub 2015 Mar 16.


The POLD3 subunit of DNA polymerase δ can promote translesion synthesis independently of DNA polymerase ζ.

Hirota K, Yoshikiyo K, Guilbaud G, Tsurimoto T, Murai J, Tsuda M, Phillips LG, Narita T, Nishihara K, Kobayashi K, Yamada K, Nakamura J, Pommier Y, Lehmann A, Sale JE, Takeda S.

Nucleic Acids Res. 2015 Feb 18;43(3):1671-83. doi: 10.1093/nar/gkv023. Epub 2015 Jan 27.


SUMO-targeted ubiquitin ligase RNF4 plays a critical role in preventing chromosome loss.

Hirota K, Tsuda M, Murai J, Takagi T, Keka IS, Narita T, Fujita M, Sasanuma H, Kobayashi J, Takeda S.

Genes Cells. 2014 Oct;19(10):743-54. doi: 10.1111/gtc.12173. Epub 2014 Sep 10.


Biochemical assays for the discovery of TDP1 inhibitors.

Marchand C, Huang SY, Dexheimer TS, Lea WA, Mott BT, Chergui A, Naumova A, Stephen AG, Rosenthal AS, Rai G, Murai J, Gao R, Maloney DJ, Jadhav A, Jorgensen WL, Simeonov A, Pommier Y.

Mol Cancer Ther. 2014 Aug;13(8):2116-26. doi: 10.1158/1535-7163.MCT-13-0952. Epub 2014 Jul 14.


Discovery and structure-activity relationship of novel 2,3-dihydrobenzofuran-7-carboxamide and 2,3-dihydrobenzofuran-3(2H)-one-7-carboxamide derivatives as poly(ADP-ribose)polymerase-1 inhibitors.

Patel MR, Bhatt A, Steffen JD, Chergui A, Murai J, Pommier Y, Pascal JM, Trombetta LD, Fronczek FR, Talele TT.

J Med Chem. 2014 Jul 10;57(13):5579-601. doi: 10.1021/jm5002502. Epub 2014 Jun 25.


Tyrosyl-DNA-phosphodiesterases (TDP1 and TDP2).

Pommier Y, Huang SY, Gao R, Das BB, Murai J, Marchand C.

DNA Repair (Amst). 2014 Jul;19:114-29. doi: 10.1016/j.dnarep.2014.03.020. Epub 2014 May 22. Review.


Identification of novel PARP inhibitors using a cell-based TDP1 inhibitory assay in a quantitative high-throughput screening platform.

Murai J, Marchand C, Shahane SA, Sun H, Huang R, Zhang Y, Chergui A, Ji J, Doroshow JH, Jadhav A, Takeda S, Xia M, Pommier Y.

DNA Repair (Amst). 2014 Sep;21:177-82. doi: 10.1016/j.dnarep.2014.03.006. Epub 2014 Apr 29.


Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.

Murai J, Zhang Y, Morris J, Ji J, Takeda S, Doroshow JH, Pommier Y.

J Pharmacol Exp Ther. 2014 Jun;349(3):408-16. doi: 10.1124/jpet.113.210146. Epub 2014 Mar 20.


PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage.

Das BB, Huang SY, Murai J, Rehman I, Amé JC, Sengupta S, Das SK, Majumdar P, Zhang H, Biard D, Majumder HK, Schreiber V, Pommier Y.

Nucleic Acids Res. 2014 Apr;42(7):4435-49. doi: 10.1093/nar/gku088. Epub 2014 Feb 3.


Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.

Murai J, Huang SY, Renaud A, Zhang Y, Ji J, Takeda S, Morris J, Teicher B, Doroshow JH, Pommier Y.

Mol Cancer Ther. 2014 Feb;13(2):433-43. doi: 10.1158/1535-7163.MCT-13-0803. Epub 2013 Dec 19.


Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel.

Maede Y, Shimizu H, Fukushima T, Kogame T, Nakamura T, Miki T, Takeda S, Pommier Y, Murai J.

Mol Cancer Ther. 2014 Jan;13(1):214-20. doi: 10.1158/1535-7163.MCT-13-0551. Epub 2013 Oct 15.


Degree of discrepancy between HbA1c and glycemia in variant hemoglobin is smaller when HbA1c is measured by new-type Arkray HPLC compared with old-type HPLC.

Koga M, Kurebayashi S, Murai J, Saito H, Miyazaki A.

Clin Biochem. 2014 Jan;47(1-2):123-5. doi: 10.1016/j.clinbiochem.2013.09.019. Epub 2013 Oct 12.


TDP1 repairs nuclear and mitochondrial DNA damage induced by chain-terminating anticancer and antiviral nucleoside analogs.

Huang SY, Murai J, Dalla Rosa I, Dexheimer TS, Naumova A, Gmeiner WH, Pommier Y.

Nucleic Acids Res. 2013 Sep;41(16):7793-803. doi: 10.1093/nar/gkt483. Epub 2013 Jun 17.


Study on the mechanism causing elevation of serum CA19-9 levels in diabetic patients.

Murai J, Soga S, Saito H, Otsuki M, Kitada T, Saisho Y, Nakamura H, Kasayama S, Koga M.

Endocr J. 2013;60(7):885-91. Epub 2013 Apr 3.


The glycated albumin to HbA1c ratio is elevated in patients with fulminant type 1 diabetes mellitus with onset during pregnancy.

Koga M, Shimizu I, Murai J, Saito H, Kasayama S, Kobayashi T, Imagawa A, Hanafusa T; Japan Diabetes Society's Committee Of Research On Type 1 Diabetes Mellitus.

J Med Invest. 2013;60(1-2):41-5.


Comparison of annual variability in HbA1c and glycated albumin in patients with type 1 vs. type 2 diabetes mellitus.

Koga M, Murai J, Morita S, Saito H, Kasayama S.

J Diabetes Complications. 2013 May-Jun;27(3):211-3. doi: 10.1016/j.jdiacomp.2012.12.001. Epub 2013 Jan 10.


Seven diverse human embryonic stem cell-derived chondrogenic clonal embryonic progenitor cell lines display site-specific cell fates.

Sternberg H, Kidd J, Murai JT, Jiang J, Rinon A, Erickson IE, Funk WD, Wang Q, Chapman KB, Vangsness CT Jr, West MD.

Regen Med. 2013 Mar;8(2):125-44. doi: 10.2217/rme.12.117. Epub 2012 Dec 18.


Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, Pommier Y.

Cancer Res. 2012 Nov 1;72(21):5588-99. doi: 10.1158/0008-5472.CAN-12-2753.


TDP2 promotes repair of topoisomerase I-mediated DNA damage in the absence of TDP1.

Zeng Z, Sharma A, Ju L, Murai J, Umans L, Vermeire L, Pommier Y, Takeda S, Huylebroeck D, Caldecott KW, El-Khamisy SF.

Nucleic Acids Res. 2012 Sep 1;40(17):8371-80. Epub 2012 Jun 26.


A human embryonic stem cell-derived clonal progenitor cell line with chondrogenic potential and markers of craniofacial mesenchyme.

Sternberg H, Murai JT, Erickson IE, Funk WD, Das S, Wang Q, Snyder E, Chapman KB, Vangsness CT Jr, West MD.

Regen Med. 2012 Jul;7(4):481-501. doi: 10.2217/rme.12.29. Epub 2012 Apr 23.


Estimation of HbA1c response to sitagliptin by change in glycated albumin level for 2 weeks.

Hamaguchi T, Koga M, Murai J, Saito H, Tamada D, Kurebayashi S, Katsuno T, Miyagawa J, Namba M.

J Diabetes Investig. 2012 Mar 28;3(2):175-8. doi: 10.1111/j.2040-1124.2011.00167.x.


Tyrosyl-DNA phosphodiesterase 1 (TDP1) repairs DNA damage induced by topoisomerases I and II and base alkylation in vertebrate cells.

Murai J, Huang SY, Das BB, Dexheimer TS, Takeda S, Pommier Y.

J Biol Chem. 2012 Apr 13;287(16):12848-57. doi: 10.1074/jbc.M111.333963. Epub 2012 Feb 27.


Estimation of Duration of Symptoms in Fulminant Type 1 Diabetes Mellitus Using HbA1c or Glycated Albumin.

Kawabe A, Seta T, Fujii S, Yamada M, Oki S, Murai J, Saito H, Koga M.

Jpn Clin Med. 2012 May 21;3:15-20. doi: 10.4137/JCM.S9509. eCollection 2012.


Serum 1,5-anhydroglucitol is low in gastrectomized men.

Murai J, Koga M, Saito H, Mukai M, Kasayama S.

Acta Diabetol. 2014 Apr;51(2):337-8. doi: 10.1007/s00592-011-0354-1. Epub 2011 Nov 23. No abstract available.


Regulation of the Fanconi anemia pathway by a SUMO-like delivery network.

Yang K, Moldovan GL, Vinciguerra P, Murai J, Takeda S, D'Andrea AD.

Genes Dev. 2011 Sep 1;25(17):1847-58. doi: 10.1101/gad.17020911.


Prediction of near-future glycated hemoglobin levels using glycated albumin levels before and after treatment for diabetes.

Koga M, Murai J, Saito H, Kasayama S.

J Diabetes Investig. 2011 Aug 2;2(4):304-9. doi: 10.1111/j.2040-1124.2011.00107.x.


Conditional deletion of Bmpr1a in differentiated osteoclasts increases osteoblastic bone formation, increasing volume of remodeling bone in mice.

Okamoto M, Murai J, Imai Y, Ikegami D, Kamiya N, Kato S, Mishina Y, Yoshikawa H, Tsumaki N.

J Bone Miner Res. 2011 Oct;26(10):2511-22. doi: 10.1002/jbmr.477.


Glycated albumin levels are higher relative to HbA1c levels in people with autoimmune acute-onset type 1 diabetes mellitus than in people with type 2 diabetes mellitus at the time of diagnosis.

Koga M, Murai J, Saito H, Aoki K, Kanehara H, Bando Y, Morita S, Kasayma S.

Diabetes Res Clin Pract. 2011 Oct;94(1):e12-4. doi: 10.1016/j.diabres.2011.06.022. Epub 2011 Jul 22.


Profiles of atherosclerotic risk factors in gastrectomized men.

Murai J, Koga M, Saito H, Mukai M, Matsumoto S, Kasayama S.

Endocr J. 2011;58(8):657-62. Epub 2011 Jun 10.


The USP1/UAF1 complex promotes double-strand break repair through homologous recombination.

Murai J, Yang K, Dejsuphong D, Hirota K, Takeda S, D'Andrea AD.

Mol Cell Biol. 2011 Jun;31(12):2462-9. doi: 10.1128/MCB.05058-11. Epub 2011 Apr 11.


Measurement of glycated hemoglobin and glycated albumin in umbilical cord: evaluation of the glycemic control indicators in neonates.

Koga M, Murai J, Saito H, Yamada Y, Mori T, Suno S, Takeuchi K, Suzuki S, Fujieda K, Kasayama S.

J Perinatol. 2011 Jun;31(6):430-3. doi: 10.1038/jp.2010.144. Epub 2010 Dec 16.


Supplemental Content

Support Center